Adverse effects of chemotherapy may be under-reported

August 15, 2006

Young breast cancer patients who receive chemotherapy may have a higher number of serious side effects than reported in clinical trials. According to a new study in the August 18 issue of the Journal of the National Cancer Institute, they may have higher health care expenditures than previously estimated.

Drug-related side effects account for an estimated 6.5% of all hospitalizations in the United States and 100,000 deaths per year. Some researchers believe that these effects are not adequately reported in clinical trials.

Michael J. Hassett, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues identified 12, 239 breast cancer patients age 63 and under through a database of medical claims made through employer-sponsored health insurance plans. They narrowed the poor to 7,052 patients who had made claims during hospitalizations and emergency room visits for side effects from chemotherapy and health care expenditures. Half received chemotherapy and half did not.

The authors observed that women who received chemotherapy were more likely to be hospitalized for side effects than those who did not. Chemotherapy recipients, on average, incurred $1,271 more per year in costs for medical expenses related to side effects and $17,617 more per year in costs for ambulatory care than women who did not receive chemotherapy.

The authors write, "Our results suggest that breast cancer chemotherapy may cause more patient suffering and higher health care costs than previously estimated. [...] Health care providers must carefully decide whether trial results can be applied to routine clinical practice."

In an accompanying editorial, John K. Erban, M.D., and Joseph Lau, M.D., of Tufts New England Medical Center and Tufts University School of Medicine in Boston, suggest that the study's methodology may have excluded under-represented populations and racial and ethnic minorities but note that the results are "important and intriguing." They write, "As new drugs of increasing efficacy and few acute toxicities emerge, the tendency will be to push them to market, and there will be few incentives for longer term toxicity studies. [...] Without careful long term tracking of late adverse effects, there is a risk that very important toxicity events will occur unnoticed."
-end-
Contacts:
  • Article: Bill Schaller, 617-632-5357, William_Schaller@dfci.harvard.edu
  • Editorial: Catherine Bromberg, cbromberg@tufts-nemc.org

    Citations: •
  • adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117.
  • Editorial: Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer -the need for vigilance. J Natl Cancer Inst 2006;98:1096-1097.

    Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

    Journal of the National Cancer Institute

    Related Chemotherapy Articles from Brightsurf:

    Chemotherapy is used to treat less than 25% of people with localized sarcoma
    UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

    Starved cancer cells became more sensitive to chemotherapy
    By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

    Vitamin D could help mitigate chemotherapy side effects
    New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

    Less chemotherapy may have more benefit in rectal cancer
    GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

    Male fertility after chemotherapy: New questions raised
    Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

    'Combo' nanoplatforms for chemotherapy
    In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

    Nanotechnology improves chemotherapy delivery
    Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

    Novel anti-cancer nanomedicine for efficient chemotherapy
    Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

    Ending needless chemotherapy for breast cancer
    A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

    A homing beacon for chemotherapy drugs
    Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

    Read More: Chemotherapy News and Chemotherapy Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.